InspireMD Inc. buy stratec
Summary
This prediction ended on 10.01.19 with a price of €110.25. Massive losses of -98.00% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
InspireMD Inc. | 5.556% | 5.556% | -7.639% | -16.352% |
iShares Core DAX® | 4.097% | 1.280% | 17.609% | 14.486% |
iShares Nasdaq 100 | 5.110% | -0.741% | 32.406% | 41.201% |
iShares Nikkei 225® | 5.333% | -0.280% | 16.646% | 10.048% |
iShares S&P 500 | 3.487% | -0.006% | 27.373% | 39.454% |
Comments by stratec for this prediction
In the thread InspireMD Inc. diskutieren
InspireMD expects Q4 2017 sales of ~$833K (+159%)
The company says the CGuard* stent is designed to prevent embolization (blocking a blood vessel) by
trapping potential emboli against the arterial wall while maintaining excellent blood flow.
* Das CGuardTM Embolic Prevention System (EPS) wurde entwickelt, um eine peri-prozedurale und späte Embolisation zu verhindern, indem mögliche Emboli gegen die Arterienwand abgefangen werden, während gleichzeitig eine ausgezeichnete Perfusion zu der äußeren Halsschlagader und den
Nebengefäßen aufrechterhalten wird.